2-(1-Methylpyrrolidin-3-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(1-Methylpyrrolidin-3-yl)acetamide
• 英文别名: 2-(1-methylpyrrolidin-3-yl)acetamide
• 化学式: C₇H₁₄N₂O
• 分子量: 142.2
• InChiKey: AHPGJSUOMGKWLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS
  申请人：DOMAINEX LIMITED

  公开号：US20160000784A1

  公开（公告）日：2016-01-07

  Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1 in which one of V and W is N, and the other of V and W is C—H; and R 1 , R 2 , R 3 and R 4 are as defined in the specification. The invention also provides uses of the compounds and compositions containing them.

  通式（I）及其盐在治疗与蛋白激酶IKKε和/或TBK-1的异常活性相关的疾病方面具有用处，其中V和W中的一个是N，另一个是C-H；R1、R2、R3和R4如规范中定义。本发明还提供了化合物的用途和含它们的组合物。
• Thienopyrimidinone NMDA receptor modulators and uses thereof
  申请人：Cadent Therapeutics, Inc.

  公开号：US10973825B2

  公开（公告）日：2021-04-13

  Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

  本文部分公开了治疗神经系统疾病（如精神分裂症和重度抑郁症）的方法，包括施用有效量的已公开杂环化合物。提供了药物组合物和制造杂环化合物的方法。这些化合物可用于调节 NMDA 受体。
• THIENOPYRIMIDINONE NMDA RECEPTOR MODUCLATORS AND USES THEREOF
  申请人：CADENT THERAPEUTICS, INC.

  公开号：US20180360837A1

  公开（公告）日：2018-12-20

  Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
• THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Cadent Therapeutics, Inc.

  公开号：US20220016117A1

  公开（公告）日：2022-01-20

  Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
• US9433622B2
  申请人：——

  公开号：US9433622B2

  公开（公告）日：2016-09-06